Bioavailability of naproxen sodium and its relationship to clinical analgesic effects
H Sevelius, R Runkel, E Segre, S S Bloomfield, H Sevelius, R Runkel, E Segre, S S Bloomfield
Abstract
1 In the first of a series of trials with naproxen sodium it was shown that patients achieved significantly earlier and higher plasma levels of naproxen when naproxen sodium was administered. 2 In a second study comparing naproxen with naproxen sodium in patients with post-partum pain, pain intensity was consistently lower for the group receiving naproxen sodium. However, statistically significant differences were not seen until 4 to 5 h after medication. 3 A final study documented that a more frequent dosage schedule of every 6 h led to clearly higher plasma levels than those achieved with an every 8 h regimen; plasma levels did not plateau. Doses up to 1,375 mg/day were well tolerated. 4 In conclusion, naproxen sodium appears to be an improved form of naproxen for use as a analgesic agent.
References
- J Pharm Sci. 1965 Jul;54(7):959-67
- Clin Pharmacol Ther. 1968 May-Jun;9(3):290-302
- Scand J Rheumatol Suppl. 1973;2:50-5
- Scand J Rheumatol Suppl. 1973;2:56-9
- Scand J Rheumatol Suppl. 1973;2:60-3
- Scand J Rheumatol Suppl. 1973;2:12-9
- Clin Pharmacol Ther. 1976 Jan;19(1):18-23
- Clin Pharmacol Ther. 1976 Sep;20(3):269-77
- Clin Pharmacol Ther. 1977 Apr;21(4):414-21
- J Pharm Sci. 1961 May;50:388-92
- Clin Pharmacol Ther. 1960 Mar-Apr;1:163-74
Source: PubMed